Literature DB >> 22281888

Hypokalemic paralysis following administration of intravenous methylprednisolone in a patient with Graves' thyrotoxicosis and ophthalmopathy.

Stelios Tigas1, Petros Papachilleos, Nikolaos Ligkros, Maria Andrikoula, Agathocles Tsatsoulis.   

Abstract

Glucocorticoids are commonly used in the treatment of patients with thyroid disorders, in particular Graves' ophthalmopathy. Thyrotoxic hypokalemic periodic paralysis (TPP) is an infrequent but potentially serious condition characterised by recurrent episodes of weakness associated with hypokalemia. We describe the development of acute hypokalemic paralysis in a middle-aged Caucasian man with recently diagnosed thyrotoxicosis and severe, active Graves' opthalmopathy who developed progressive flaccid paralysis 12 hours following intravenous administration of methylprednisolone. Rechallenge with the same dose after the patient had been rendered euthyroid did not provoke TPP. Clinicians should exercise caution when administering high-dose glucocorticoids during thyrotoxicosis as there is a risk of provoking hypokalemic paralysis in susceptible patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22281888     DOI: 10.14310/horm.2002.1323

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  3 in total

Review 1.  Acute thyroid eye disease (TED): principles of medical and surgical management.

Authors:  D H Verity; G E Rose
Journal:  Eye (Lond)       Date:  2013-02-15       Impact factor: 3.775

2.  Potassium Supplementation to Prevent Severe Hypokalemia and Paralysis after High-Dose Methylprednisolone for Ophthalmopathy in Uncontrolled Graves Disease: A Case Report.

Authors:  Alix-Anne Gendron; Antoine Marquis; Carolanne Mongeon; Andreea Statie; Audrey Bouchard; Michael Khazaka
Journal:  Can J Hosp Pharm       Date:  2022-07-04

3.  Steroids and Thyrotoxicosis Precipitate Periodic Paralysis.

Authors:  Rizwan Ahamed; Sarah McCalley; Anupam A Sule
Journal:  Cureus       Date:  2018-01-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.